Kobayashi Profit Increases Due to Success in Generic Drug Business
This article was originally published in PharmAsia News
For the third fiscal quarter, Kobayashi Pharmaceutical's profits increased by 2.6 percent even as its revenue decreased by 11 percent. President Yutaka Kobayashi credits the increase to its mergers and acquisitions strategies in its generic drug business. Kobayashi's generic, metabolic syndrome drug Naishitoru, launched in 2006, has brought in ¥3.5 billion ($32.7 million) in annual revenue. In 2005, Kobayashi bought the brand Inochi no Haha, a generic menopause drug with ¥0.3 billion ($2.8 million) in estimated annual revenue. In the first year following the purchase, Inochi no Haha surpassed the ¥1 billion in revenue. Already a major player in the generic drug industry, Kobayshi sees more space to grow in this area, and its M&A will not only focus on large companies, but also on mid-sized firms. (Click for more-Japanese language
You may also be interested in...
Due to strained resources and the slew of emergency use authorizations being requested by sponsors because of the COVID-19 crisis, the agency will now periodically publish Notices of Availabilities in the Federal Register instead of publishing immediately as the EUAs are handed out. However, companies will still get their NOA letters and can start marketing their products, and the agency will post the announcements sooner on its website.
Diabetes-care company Bigfoot Biomedical announced it raised $55m in a Series C round to support US FDA submission for its insulin delivery system.
The US FDA released three device-related close-out letters in May.